CTOR Citius Oncology, Inc.
$0.92▲ +0.82%
Healthcare
Other
After hours
$0.93▲ +1.36%
Sep 11, 5:40 PM ET
Volume 130.5K
Avg Volume (10D) 49.1K
Key Metrics & Fundamentals
Market Cap
$97.03M
P/E Ratio
–
Div Yield
–%
52W Range
0.49 - 2.25
% vs 50 MA
26.87%
% vs 200 MA
2.97%
RSI-14
64.9
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.97
Free Cash Flow
-$4.71M
Gross Rev
$1.49M
Gross Profit
$1.00M
EBITDA
-$6.72M
COGS
$491,843
Operating Exp
$9.72M
Operating Income
-$8.72M
EBIT
-$8.72M
Pretax Income
-$9.03M
Net Income
-$8.92M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
PR Newswire · Sep 3, 2026 12:30 PM
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum
InvestorsHub · Aug 17, 2026 12:28 PM
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
PR Newswire · Aug 14, 2026 8:30 PM
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
PR Newswire · Aug 14, 2026 8:30 PM
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
PR Newswire · Aug 12, 2026 12:00 PM
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
PR Newswire · Aug 5, 2026 1:17 PM
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
PR Newswire · Jul 21, 2026 1:17 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See CTOR's money flow as a full page
Social Sentiment
No Reddit posts found for CTOR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.